Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. - Wikidata - awgldk - TriplyDB

Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.

Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.

http://www.wikidata.org/entity/Q42990950

about

The phantom menace.Comparison of Conventional PCR with Real-Time PCR and Branched DNA-Based Assays for Hepatitis C Virus RNA Quantification and Clinical Significance for Genotypes 1 to 5 Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease Ribavirin Antagonizes the In Vitro Anti-Hepatitis C Virus Activity of 2'-C-Methylcytidine, the Active Component of Valopicitabine Viral Determinants of Resistance to Treatment in Patients with Hepatitis C Use of Sequence Analysis of the NS5B Region for Routine Genotyping of Hepatitis C Virus with Reference to C/E1 and 5' Untranslated Region Sequences Discovery and Characterization of Substituted Diphenyl Heterocyclic Compounds as Potent and Selective Inhibitors of Hepatitis C Virus Replication Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors A new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutants The unfinished legacy of liver transplantation: emphasis on immunology.Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome.Mechanistic studies of electrophilic protease inhibitors of full length hepatic C virus (HCV) NS3.Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6 Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling Treatment of hepatitis C virus infection Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles.Direct-acting antivirals for chronic hepatitis C.Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies.New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy.Sequence diversity of hepatitis C virus: implications for immune control and therapy.Challenges and successes in developing new therapies for hepatitis C.Established and emerging therapies for the treatment of viral hepatitis.Treating viral hepatitis C: efficacy, side effects, and complications.Improving anti-hepatitis C virus therapy.Antiviral treatment of hepatitis C.Targets of emerging therapies for viral hepatitis B and C.New treatment strategies against hepatitis C viral infection.Present and future therapy for hepatitis C virus.Improving the treatment of hepatitis C infection in the UK.Toll-like receptors, RIG-I-like RNA helicases and the antiviral innate immune response.Novel protease and polymerase inhibitors for the treatment of hepatitis C virus infection.Old and emerging therapies in chronic hepatitis C: an update.HCV genetic variability: from quasispecies evolution to genotype classification.Serine protease inhibitors as anti-hepatitis C virus agents.Antiviral therapy for hepatitis C virus: beyond the standard of care.Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C.Novel therapies for hepatitis C - one pill fits all?Hepatitis C virus infection and related liver disease: the quest for the best animal model

P2860

Q27472943-B0F42C4E-2030-4847-976D-387810CDC65B Q27473038-FBA35209-A999-4EBF-817F-8833E4047C67 Q27473126-8F970EC3-FB25-4D80-A43A-0395D42DB445 Q27477522-8B4E507A-5B60-41CC-ACF9-74BEFC4FBC23 Q27478062-47289863-160B-411F-AFFE-0B812BD78B82 Q27478359-355B0DFD-4DED-4257-8248-597571BBCC46 Q27485724-49050C65-EB84-4396-A360-C22CF8FB49B6 Q27487391-CACB58EB-F4C8-40B6-8309-6CC0852AC857 Q27490545-3FDE0958-5A95-4EA9-BF9B-21D8265C27CC Q28481038-4C9CE392-00D7-422B-9C93-40703A6E723C Q28541048-7A7C9206-5DF2-4472-9FB3-FC9F999A72D7 Q30352760-CCCBDF50-9BDD-4A8F-BDFD-D41A4E4615CB Q30655795-D0F323B0-3AD8-431C-8E4C-7BB54E13E52A Q33285370-76BA2A0A-7628-4B64-AC00-BA1042E1C730 Q33826766-2F0FCC84-BCBB-495C-B3D2-781EBA41E254 Q33899320-F8762ADE-E345-4769-86B1-2DC0526FF3B6 Q34099424-20F961C3-077D-494D-B23E-065F06E2CD2C Q34232434-5F5E6433-A25D-4A3A-8E34-9E7C70A73F26 Q34557595-017AB9F1-C665-4705-80A8-AC1375F3A7CD Q35565927-E0DEA2AB-4052-40B5-BB72-1C777950C23C Q35653358-F223E300-11C1-4CFC-9968-A2E00C012626 Q36179696-B5A989D1-A281-4D52-B6F3-326C869068AA Q36233823-BC7F99D1-2732-484E-A395-7F6A1B98EC13 Q36478120-01419C38-5F3D-4280-896C-125DE54134D0 Q36564615-CCDB190C-5A58-4C78-8AE1-448632F49933 Q36569749-AAFB005D-828D-47BF-8156-523F59363B17 Q36613917-1EC23E4C-381D-4216-A5A8-75B6A311B75C Q36653655-C14268E0-943E-4FA3-98B2-5AA7DADB44DB Q36655935-A964C426-9676-411C-B060-8700FC198535 Q36670887-5B4DE2FE-247B-4590-8376-1C673AABEB72 Q36719683-EDDBB020-B559-413B-A487-B7A2AD74DD6B Q36898663-9A3B445D-0DCB-4656-8E2B-D4C7BD9467F3 Q36904844-BBE9D447-2CBF-4BEC-A15C-5AC6BF6E06B2 Q37035294-6E0C14A3-A90B-4CF3-84C3-300A48429836 Q37425275-5D3E145E-D960-4D6C-AA46-63BCC407AC61 Q37503337-0CAB3581-8CE8-404A-A5E1-7A35B5C727DA Q37945201-AB1F0DC8-DB89-4711-878D-FF2D54D5D1C1 Q37990840-841BD7FF-9655-4BD0-A694-405EB68E406C Q38117549-207E231A-E086-4CC0-9CAF-353ABB580D05 Q38125192-F3C3E0DD-5B6C-4D24-A870-09C4FD571873

P2860

Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.

http://www.wikidata.org/entity/Q42990950

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Antiviral efficacy of NS3-seri ...... genotype 2 and 3 hepatitis C.

@en

Antiviral efficacy of NS3-seri ...... genotype 2 and 3 hepatitis C.

@nl

type

label

Antiviral efficacy of NS3-seri ...... genotype 2 and 3 hepatitis C.

@en

Antiviral efficacy of NS3-seri ...... genotype 2 and 3 hepatitis C.

@nl

prefLabel

Antiviral efficacy of NS3-seri ...... genotype 2 and 3 hepatitis C.

@en

Antiviral efficacy of NS3-seri ...... genotype 2 and 3 hepatitis C.

@nl

P1433

Q42990950-615D554D-D7C6-4C4C-B65D-E78CD2BD60A4

P1476

Q42990950-A3A1F3EE-8ED7-4953-815D-9747D5F91658

P2093

Q42990950-2CB82738-C8E1-4118-AA86-1E493750D2FF

Q42990950-464F77A4-DE2F-4F53-BA07-2AE88D7F6542

Q42990950-661C152A-3D9B-42B0-9496-8778A7771772

Q42990950-72E097C5-8F83-4109-B4B3-AEC7E3A9E9BC

Q42990950-948BAFD9-56B4-421B-8E27-9B79C28E532A

Q42990950-A0FC0ADE-7E00-4063-9945-189F85F39195

Q42990950-A91A3489-FA8D-4DF7-8697-3EF92D627C2A

Q42990950-A9B033E1-00FC-4A8A-818C-11A236205E64

Q42990950-B3E3DAC1-948D-49AF-B6D6-00BE4AEB2CE4

Q42990950-E077DC46-D4A5-4AF7-B025-2285CBC22FED

P2860

Q42990950-FC82A747-878D-44C3-B00B-E3A12BF0D249

P304

Q42990950-B36082D7-09B2-4F38-8617-2D31A9E5E0D9

P31

Q42990950-5991D962-4C20-4D8C-9E23-2B30E79BB69C

P356

Q42990950-F5C128CB-AC1F-48FB-BD18-7ED56E3F8B50

P407

Q42990950-F0B7AB9D-EBE9-4F91-8D34-E10847C0A47E

P433

Q42990950-BDCB2BBA-8C7E-493E-AA52-C0716558A447

P478

Q42990950-DC0B1B31-B73A-436B-B149-ADF215D465A2

P577

Q42990950-69D25567-3525-43B9-9E16-703C66A1D979

P5875

Q42990950-CEC14451-A780-4711-9EBC-F2F8212A3617

P698

Q42990950-A4FD6043-95F0-433E-8133-DCBB1373C9E4

P356

P1433

P1476

Antiviral efficacy of NS3-seri ...... genotype 2 and 3 hepatitis C.

@en

P2093

Chan-Loi Yong

http://www.w3.org/2001/XMLSchema#string

Cristina Avendano

http://www.w3.org/2001/XMLSchema#string

Gerhard G Steinmann

http://www.w3.org/2001/XMLSchema#string

Gerhard Nehmiz

http://www.w3.org/2001/XMLSchema#string

Heiner Wedemeyer

http://www.w3.org/2001/XMLSchema#string

Henk W Reesink

http://www.w3.org/2001/XMLSchema#string

Holger Hinrichsen

http://www.w3.org/2001/XMLSchema#string

Markus Reiser

http://www.w3.org/2001/XMLSchema#string

Neus Riba

http://www.w3.org/2001/XMLSchema#string

Yves Benhamou

http://www.w3.org/2001/XMLSchema#string

P2860

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

P304

832-835

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.20612

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P577

2005-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8001763

http://www.w3.org/2001/XMLSchema#string

P698

15732092

http://www.w3.org/2001/XMLSchema#string